Previous DXB Announcement: Completion of Ph2a Trial Recruitment (06 Dec 2016)
After all 27 patients had been enrolled....
Dimerix CEO Kathy Harrison said, “Dimerix recently reported interim data from Part A of the trial which showed a good safety profile and encouraging signs of reduction of proteinuria. This trend has continued, hence the Company is confident that the current patient cohort will provide the data needed to support planning for part Part B of the study which will focus on the efficacy outcomes for the treatment.”
DXB Share Price, page-63
-
- There are more pages in this discussion • 277 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
42.0¢ |
Change
-0.025(5.62%) |
Mkt cap ! $231.2M | |||
| Open | High | Low | Value | Volume |
| 43.5¢ | 44.0¢ | 41.8¢ | $1.239M | 2.905M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 257588 | 42.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.5¢ | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| DXB (ASX) Chart |